GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Cyclically Adjusted PB Ratio

WAVE Life Sciences (WAVE Life Sciences) Cyclically Adjusted PB Ratio : 1.52 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Cyclically Adjusted PB Ratio?

As of today (2024-04-28), WAVE Life Sciences's current share price is $4.66. WAVE Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $3.07. WAVE Life Sciences's Cyclically Adjusted PB Ratio for today is 1.52.

The historical rank and industry rank for WAVE Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

WVE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.27   Med: 1.61   Max: 2.21
Current: 1.52

During the past years, WAVE Life Sciences's highest Cyclically Adjusted PB Ratio was 2.21. The lowest was 1.27. And the median was 1.61.

WVE's Cyclically Adjusted PB Ratio is ranked better than
53.04% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs WVE: 1.52

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

WAVE Life Sciences's adjusted book value per share data for the three months ended in Dec. 2023 was $0.333. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.07 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


WAVE Life Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for WAVE Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Cyclically Adjusted PB Ratio Chart

WAVE Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.64

WAVE Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.64

Competitive Comparison of WAVE Life Sciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, WAVE Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WAVE Life Sciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Cyclically Adjusted PB Ratio falls into.



WAVE Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

WAVE Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.66/3.07
=1.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WAVE Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, WAVE Life Sciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.333/129.4194*129.4194
=0.333

Current CPI (Dec. 2023) = 129.4194.

WAVE Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.467 98.326 -0.615
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -0.279 99.070 -0.364
201503 0.000 99.621 0.000
201506 0.056 100.684 0.072
201509 -0.160 100.392 -0.206
201512 7.122 99.792 9.236
201603 6.799 100.470 8.758
201606 7.096 101.688 9.031
201609 6.438 101.861 8.180
201612 5.738 101.863 7.290
201703 4.972 102.862 6.256
201706 6.812 103.349 8.530
201709 5.973 104.136 7.423
201712 5.017 104.011 6.243
201803 3.931 105.290 4.832
201806 4.755 106.317 5.788
201809 3.623 106.507 4.402
201812 2.489 105.998 3.039
201903 5.747 107.251 6.935
201906 4.676 108.070 5.600
201909 3.348 108.329 4.000
201912 1.856 108.420 2.215
202003 0.603 108.902 0.717
202006 -0.126 108.767 -0.150
202009 2.219 109.815 2.615
202012 1.697 109.897 1.998
202103 1.060 111.754 1.228
202106 0.432 114.631 0.488
202109 0.575 115.734 0.643
202112 0.543 117.630 0.597
202203 -0.001 121.301 -0.001
202206 0.357 125.017 0.370
202209 -0.052 125.227 -0.054
202212 -0.519 125.222 -0.536
202303 -0.354 127.348 -0.360
202306 -0.525 128.729 -0.528
202309 -0.409 129.860 -0.408
202312 0.333 129.419 0.333

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


WAVE Life Sciences  (NAS:WVE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


WAVE Life Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences (WAVE Life Sciences) Business Description

Traded in Other Exchanges
Address
Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.
Executives
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan director